Enhanced kynurenine levels within the tumor microenvironment stimulates AHR activation within T-cells resulting in elevated PD1 expression, which in combination with tumor cell intrinsic PDL1 expression introduce immune checkpoints leading to immune tolerance [123]. This evidence concerns the gene AHR and neoplasm.